Fully Optimised Aptamers

Introducing OptimersTM
3rd October 2018
 
Proprietary process with validated improvement in delivery and performance

OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of  OptimersTM – the new standard for our custom development services.

Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]

Aptamer Group Secures $2.2m Series A Investment

Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.

Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]

  • Comparing healthy to disease state cells using aptamers

Aptamer Application: Biomarker Discovery

22nd August, 2017.
Biomarker Discovery

A biomarker is a measurable indicator showing the presence or severity of a disease state. Using biomarkers to differentiate between healthy and diseased cells can enable the development of specific diagnostics, research tools and targeted therapeutics.

Biomarker Discovery using Aptamers

Traditional biomarker discovery is a long process and relies on multiple comparisons using various […]

  • Aptamer, Flow Cytometry, Data, Stain, Antibody Alternative

Aptamer Application: Flow Cytometry

1st August, 2017.
Flow Cytometry
Flow Cytometry is a technique used to identify biomarkers on cell surfaces and intracellular molecules. Most flow cytometers use fluorescently labelled antibodies to differentiate between cells expressing different markers.

Initially the cell sample is suspended, stained with a fluorescent label and washed to remove any non-specific binding. The suspension is introduced into the […]